Insmed Inc.'s stock lost more than half of its value Thursday after the Richmond, Va.-based firm said Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor 1 (IGF-1) and its binding protein IGFBP-3, failed to improve endurance, muscle function or strength or quality of life in patients with myotonic muscular dystrophy (MMD), a potentially life-threatening genetic disorder. (BioWorld Today) Read More
